Risk of Locoregional Recurrence After Breast Cancer Surgery by Molecular Subtype-a Systematic Review and Network Meta-analysis

Overview

Journal Ir J Med Sci

Specialty General Medicine

Date 2024 Sep 27

PMID 39331262

Authors

Lily Nolan

Matthew G Davey

Gavin G Calpin

Eanna J Ryan

Michael R Boland

Affiliations

Soon will be listed here.

Abstract

Background: The prevention of locoregional recurrence (LRR) is crucial in breast cancer, as it translates directly into reduced breast cancer-related death. Breast cancer is subclassified into distinct intrinsic biological subtypes with varying clinical outcomes.

Aims: To perform a systematic review and network meta-analysis (NMA) to determine the rate of LRR by breast cancer molecular subtype.

Methods: A NMA was performed as per PRISMA-NMA guidelines. Molecular subtypes were classified by St Gallen expert consensus statement (2013). Analysis was performed using R and Shiny.

Results: Five studies were included including 6731 patients whose molecular subtypes were available. Overall, 47.3% (3182/6731) were Luminal A (LABC: estrogen receptor (ER) + /human epidermal growth factor receptor-2 (HER2) - /progesterone receptor (PR) + or Ki-67 < 20%), 25.5% (1719/6731) were Luminal B (LBBC: ER + /HER2 - /PR - or Ki-67 ≥ 20%), 11.2% (753/6731) were Luminal B-HER2 + (LBBC-HER2: ER + /HER2 +), 6.9% (466/6731) were HER2 + (HER2 ER - /HER2 +), and finally 9.1% (611/6731) were triple-negative breast cancer (TNBC: ER - /HER2 -). The median follow-up was 74.0 months and the overall LRR rate was 4.0% (271/6731). The LRR was 1.7% for LABC (55/3182), 5.1% for LBBC (88/1719), 6.0% for LBBC-HER2 (45/753), 6.0% for HER2 (28/466), and 7.9% for TNBC (48/611). At NMA, patients with TNBC (odds ratio (OR) 3.73, 95% confidence interval (CI) 1.80-7.74), HER2 (OR 3.24, 95% CI 1.50-6.99), LBBC-HER2 (OR 2.38, 95% CI 1.09-5.20), and LBBC (OR 2.20, 95% CI 1.07-4.50) were significantly more likely to develop LRR compared to LABC.

Conclusion: TNBC and HER2 subtypes are associated with the highest risk of LRR. Multidisciplinary team discussions should consider these findings to optimize locoregional control following breast cancer surgery.

Citing Articles

Development, Content Validity and Usability of a Self-Assessment Instrument for the Lifestyle of Breast Cancer Survivors in Brazil.

de Souza J, Kliemann N, Vieira F, Al Nahas A, Reitz L, Aglago E Nutrients. 2024; 16(21).

PMID: 39519541 PMC: 11547887. DOI: 10.3390/nu16213707.

References

McVeigh T, Boland M, Lowery A . The impact of the Biomolecular Era on breast cancer surgery. Surgeon. 2016; 15(3):169-181. DOI: 10.1016/j.surge.2016.09.007. View

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

Kneubil M, Brollo J, Botteri E, Curigliano G, Rotmensz N, Goldhirsch A . Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction. Eur J Surg Oncol. 2013; 39(3):260-5. DOI: 10.1016/j.ejso.2012.12.004. View

Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19):10869-74. PMC: 58566. DOI: 10.1073/pnas.191367098. View

Rakha E, Green A . Molecular classification of breast cancer: what the pathologist needs to know. Pathology. 2017; 49(2):111-119. DOI: 10.1016/j.pathol.2016.10.012. View

Parker J, Mullins M, Cheang M, Leung S, Voduc D, Vickery T . Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27(8):1160-7. PMC: 2667820. DOI: 10.1200/JCO.2008.18.1370. View

Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thurlimann B . Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9):2206-23. PMC: 3755334. DOI: 10.1093/annonc/mdt303. View

Vuong D, Simpson P, Green B, Cummings M, Lakhani S . Molecular classification of breast cancer. Virchows Arch. 2014; 465(1):1-14. DOI: 10.1007/s00428-014-1593-7. View

Meyers M, Klauber-DeMore N, Ollila D, Amos K, Moore D, Drobish A . Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol. 2011; 18(10):2851-7. DOI: 10.1245/s10434-011-1665-8. View

10.

Jwa E, Shin K, Kim J, Park Y, Jung S, Lee E . Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment. Cancer Res Treat. 2016; 48(4):1363-1372. PMC: 5080807. DOI: 10.4143/crt.2015.456. View

11.

Truong P, Sadek B, Lesperance M, Alexander C, Shenouda M, Raad R . Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?. Int J Radiat Oncol Biol Phys. 2013; 88(1):57-64. DOI: 10.1016/j.ijrobp.2013.09.024. View

12.

Christiansen P, Al-Suliman N, Bjerre K, Moller S . Recurrence pattern and prognosis in low-risk breast cancer patients--data from the DBCG 89-A programme. Acta Oncol. 2008; 47(4):691-703. DOI: 10.1080/02841860802056594. View

13.

Haffty B, Fischer D, Beinfield M, MCKHANN C . Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys. 1991; 21(2):293-8. DOI: 10.1016/0360-3016(91)90774-x. View

14.

Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V . Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 366(9503):2087-106. DOI: 10.1016/S0140-6736(05)67887-7. View

15.

Lowery A, Kell M, Glynn R, Kerin M, Sweeney K . Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat. 2011; 133(3):831-41. DOI: 10.1007/s10549-011-1891-6. View

16.

McGuire A, Lowery A, Kell M, Kerin M, Sweeney K . Locoregional Recurrence Following Breast Cancer Surgery in the Trastuzumab Era: A Systematic Review by Subtype. Ann Surg Oncol. 2017; 24(11):3124-3132. DOI: 10.1245/s10434-017-6021-1. View

17.

Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2013; 138(2):241-56. PMC: 4086638. DOI: 10.5858/arpa.2013-0953-SA. View

18.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

19.

Allison K, Hammond M, Dowsett M, McKernin S, Carey L, Fitzgibbons P . Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020; 38(12):1346-1366. DOI: 10.1200/JCO.19.02309. View

20.

Cheang M, Chia S, Voduc D, Gao D, Leung S, Snider J . Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009; 101(10):736-50. PMC: 2684553. DOI: 10.1093/jnci/djp082. View